Click through these 5 statements about the "gliflozin" class of diabetes drugs for a test of your recall and retention.
Significant reductions were seen in MACE, renal disease progression in patients with high CV risk taking canagliflozin.
A meta-analysis compared the renal side effects of SGLT2 inhibitors in patients with type 2 diabetes.
Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.
Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.
Our February list includes updated guidelines for pediatric obesity, American Heart Assoc. statement on meal timing & frequency, and diabetes risks.
The risk of urinary tract infections (UTIs), but not necessarily genital infections, may vary by agent within the SGLT2 inhibitor class.
Our January list includes new care guidelines for neuropathy, updates to oral medication recommendations, and long-term RYGB outcomes for adolescents.
SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and more – we’ve compiled a list of this year’s most popular articles on Endocrinology Network.